 Zynerba failed a phase 3 study using Zygel to treat the entire Fragile X syndrome population. However, the path forward remains targeting those with methylation of the FMR1 gene. An FDA meeting is expected to take place Q4 2020, where the company will discuss a potential path forward using Zygel to treat Fragile X syndrome patients with FMR1 gene. 